摘要
目的研究淋病奈瑟球菌耐氟喹诺酮类药物与gyrA和parC基因突变的相关性。方法采用E试验测定30株临床分离的淋病奈瑟球菌对环丙沙星的MIC。PCR法检测30株淋病奈瑟球菌喹诺酮耐药决定区(QRDR)相关gyrA和parC基因并测序分析。结果淋病奈瑟球菌对环丙沙星的耐药率达到100%,所有耐氟喹诺酮菌均存在gyrA基因双位点突变,20株高水平耐氟喹诺酮菌(MIC≥4mg/L)均存在gyrA基因双位点突变和parC单(或双)位点突变。结论gyrA和parC基因突变在淋病奈瑟菌对氟喹诺酮类药物耐药中起着重要作用,gyrA和parC基因同时突变会导致耐药性增强。
Objective To study the relationship between fluoroquinolone resistance in Neisseria gonorrhoeae and mutations in gyrA and/or parC genes. Methods Thirty N. gonorrhoeae isolates were collected to test the minimum inhibitory concentrations （MICs） of ciprofloxacin by E test method. The gyrA and parC genes containing quinolone resistance-determining region （QRDR） were amplified by PCR. The amplicons were directly analyzed by DNA suquencing. Results All the strains （100%） were resistant to ciprofloxacin. All fluoroquinolone-resistant strains showed double-point mutations in gyrA gene. And 20 high-level fluoroquinolone-resistant strains （MIC≥4 nag/L） had double-point mutations in gyrA gene and a single or doublepoint mutation（s） in parC gene. Conclusions Mutations in gyrA and/or parC genes play an important role in the development of fluoroquinolone resistance in N. gonorrhoeae. The concomitant mutation in both gyrA and parC genes can enhance fluoroquinolone resistance in N. gonorrhoeae.
出处
《中国感染与化疗杂志》
CAS
2006年第2期89-91,共3页
Chinese Journal of Infection and Chemotherapy
关键词
淋病奈瑟球菌
最低抑菌浓度
基因突变
Neisseria gonorrhoeae
Minimum inhibitory concentration
Gene mutation
